Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients
Authors' conclusion
Persistent lowering of SU significantly reduced Fib-4 scores, implying a possible effect on NAFLD progression.
Study context
- Population
- Chronic refractory gout patients in two 6-month pegloticase RCTs; Non-alcoholic fatty liver disease (NAFLD) assessed by Fib-4 index
- Participants
- 36 vs 43
- Comparison
- Pegloticase biweekly vs placebo
- Pegloticase respondersn = 36
- Placebon = 43reference
- Primary endpoint
- Change in Fib-4 score
- Follow-up
- 6 months
Methodological detailsretrospective data analysis, 6-month trials, placebo-controlled
- Retrospective data analysis
- 6-month trials
- Placebo-controlled
Primary result
As reported in the abstract
Pegloticase responders
0.13
SD 0.62
Placebo
0.26
SD 0.41
P = 0.048
Further findings
| Outcome | Pegloticase responders | Placebo | P value |
|---|---|---|---|
| Change in Fib-4, patients with baseline Fib-4 >1.3 (subgroup, n=27) | −0.15 (SD 0.67) | 0.7 (SD 0.42) | P = 0.04 |
| Baseline Fib-4Mean | 1.40 (SD 0.86) | 1.04 (SD 0.53) |
Correlation of serum urate (SU) AUC over 6 months with change in Fib-4
- R
- 0.33 (p=0.0004)
Multivariable analysis: SU AUC the only significant contributor to change in Fib-4
- SU AUC
- P = 0.018
Original publication
Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. Clin Exp Rheumatol. Published 29 November 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →